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Solid dispersions were prepared by a conventional solvent evaporation method from the water-insoluble model drug 10-hydroxy-
camptothecin (HCPT) and monomethoxypoly(ethylene glycol) 2000 (mPEG 2000). And then one type of novel biodegradable
nanoparticles,thesoliddispersion(HCPT/mPEG-CHO)graftedwithcarboxymethylchitosan(HCPT/mPEG-g-CMCTS)wassyn-
thesized. The increase in HCPT solubility of solid dispersion was up to 21-fold compared with the original drug. With the
increasing of the amount of mPEG-CHO, solubility of HCPT was from 7.71μg/mL to 25.82μg/mL. Colloid systems based on solid
dispersion were stable in aqueous medium at 5◦C. After 5 months storage at 25◦C, the solid dispersions do not change at all.
HCPT/mPEG-g-CMCTS was synthesized by grafting reaction of carboxymethylchitosan with mPEG-CHO to form Schiﬀ base
which is sensitive to acid environment. The release rate of HCPT from this conjugate in pH 5.4 was much higher than that in the
environment of pH 7.4 and p H 4.5. The cumulative release percentages are 45%, 25%, and 15%, respectively. The cumulative
release percentage of HCPT in conjugate was only 15% within 85h while the original drug was up to 70% in pH 7.4, showing
a signiﬁcant slow-release property. This drug model can be attractive candidates as delivery biosystems in tumor therapy.
1.Introduction
10-hydroxycamptothecin(HCPT),thenaturalcamptothecin
(CPT) analogue, has shown to have a strong antitumor
activity against gastric carcinoma, hepatoma, leukemia, and
tumor of head and neck in clinical practice [1, 2]. However,
the therapeutic potential has been restricted by its low
aqueous solubility, in vitro and in vivo instability. Many
recent attempts have been made to improve the shortcom-
ings of HCPT [3–5]. Amongst them is the solid dispersion
of the drug into an inert, hydrophilic polymer matrix,
which can greatly improve the water solubility of HCPT.
Solid dispersions are generally prepared by either a solvent
method, whereby the drug and carrier are dissolved in a
mutual solvent followed by solvent removal, or by a melting
method, whereby drug-carrier mixtures are prepared by
comelting/cooling [1, 6, 7]. Another solution is the drug
being wrapped into amphiphilic micelles so as to keep stable
and release slowly while maintaining their therapeutic eﬃ-
cacy [8–11].
PEGs are widely used as vehicles for solid dispersions
because of their rapid solidiﬁcation rate, capability of form-
ing solid drug solutions, low toxicity, and low costs [12, 13].
Carboxymethylchitosan has been found for the application
in biomedical areas because of its biocompatibility and
nontoxicity. Besides, due to the presence of reactive amino
groups, hydroxyl groups, and carboxyl groups, it can be
modiﬁed easily to create nano- and microparticles or porous
hydrogelswhichcanbeemployedinawiderangeofbiomed-
ical applications, such as drug or gene delivery systems
[14, 15].
Our long-term aim is to develop a slow-release and
acid-activity formulation of HCPT [16–18], which could be
useful as attractive candidates in tumor therapy. The present
investigation reports a mild method for the preparation
of solid dispersions via amino groups grafted with mPEG-
CHO. Solid dispersions were prepared by conventional
solvent evaporation method and characterized by Fourier
transform infrared (FTIR) spectroscopy. We have shown that2 ISRN Pharmaceutics
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Scheme 1: Synthesis scheme of CMCTS-g-mPEG-CHO/HCPT.
the interaction between mPEG and HCPT aﬀected drug
solubility and stability of drug in the polymer matrix. In this
report, we provide evidence that HCPT release from grafted
carboxymethylchitosan nanoparticles is signiﬁcantly slow
and sensitive to the tumor environment.
2. Methods
2.1. Materials. Carboxymethylchitosan (Mw = 360000) was
synthesized by ourselves. Poly(ethylene glycol)methyl ether
(mPEG, Mn = 2000) was purchased from Sinopharm
Chemical Reagent Co. Ltd. Hydroxycamptothecin (HCPT)
was purchased from JUNJIE Bio-Technology Co. Ltd. All
these materials and other chemicals used in this article were
analytic reagent (AR) grade and used as received without
further puriﬁcation.
2.2. Synthesis of mPEG-Aldehyde (mPEG-CHO). mPEG-
aldehyde was ﬁrst prepared by oxidation of mPEG with
DMSO/acetic anhydride. After mPEG was completely dis-
solved into anhydrous DMSO/chloroform solution (90/10,
v/v), acetic anhydride was added gradually into the reaction
system under the protection of nitrogen atmosphere. The
molar ratio of acetic anhydride to mPEG was 12. The
reaction system was kept at ambient temperature for 24h
under the nitrogen atmosphere and ﬁnally precipitated with
excess precold diethyl ether. The mixture was ﬁltered and the
obtained crude product of mPEG-aldehyde was reprecipi-
tated twice from chloroform solution with precold diethyl
ether. After the drying process, the white mPEG-aldehyde
powder was obtained and kept in desiccators for further use.
2.3. Preparation of Solid Dispersion (HCPT/mPEG-CHO).
Solid dispersions of HCPT in mPEG-CHO were prepared
in diﬀerent ratios (Table 1) by conventional solvent evapo-
ration method. Brieﬂy, in conventional solvent evaporation
method, drug and carrier were dissolved in minimum vol-
ume of methanol and chloroform. The reaction mixture was
stirred at about 30◦C for 24h; the solvents were removed
under vacuum in a rotavapor at 30◦C for 0.5h. The resultant
solid dispersion was kept in refrigerator for 2 days to harden.
Dispersions were then pulverized in mortar and pestle, and
then stored in a desiccator at room temperature.ISRN Pharmaceutics 3
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Figure 1: FTIR spectra of HCPT/mPEG-CHO (a), mPEG-CHO
(b), and HCPT (c).
Table 1:Composition(w/w)ofsoliddispersionsofHCPTprepared
by conventional solvent evaporation method.
Formulation HCPT mPEG-CHO
HCPT/mPEG-CHO (1) 1 100
HCPT/mPEG-CHO (2) 2 100
HCPT/mPEG-CHO (3) 3 100
HCPT/mPEG-CHO (4) 4 100
HCPT/mPEG-CHO (5) 5 100
2.4. Synthesis of Grafted Carboxymethylchitosan Nanoparti-
cleswithSolid Dispersion(HCPT/mPEG-g-CMCTS). HCPT/
mPEG-g-CMCTS was synthesized by alkylation of carbox-
ymethylchitosan followed by Schiﬀ base formation as shown
in Scheme 1. CMCTS and HCPT/mPEG-CHO (Compo-
sition (w/w) of solid dispersions of HCPT is 4/100) were
dissolved in 50mL water separately; CMCTS/water solution
was added to the HCPT/mPEG-CHO water solution drop by
drop by magnetic stirring. The reaction mixture was stirred
at 40◦C for 24h. The solution containing carboxymethylchi-
tosan nanoparticles was puriﬁed by dialysis for 3 days against
distilled water, then ﬁltered to remove unreacted HCPT and
freeze-dried. In the reaction, CMCTS (amino content) and
HCPT/mPEG-CHO (aldehyde content) were mixed together
at the molar ratio of 1/1.
2.5. Characterization of HCPT/mPEG-CHO
and HCPT/mPEG-g-CMCTS
2.5.1. Fourier Transform Infrared Spectroscopy (FTIR). FTIR
spectra were performed at room temperature using Nicolet-
5700 Infrared Spectrophotometer (USA). The characteristic
absorption bands were detected at wavenumbers ranging
from 500 to 4500cm−1 using a KBr-pellet method.
2.5.2. 1H Nuclear Magnetic Resonance Analysis (NMR). 1H
NMR spectra were obtained on a Bruker DRX 400MHz
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Figure 2: FTIR spectra of mPEG (a) and mPEG-CHO (b).
Table 2: Results of drug loading eﬃciency, graft volume, grafting
degree of substitution, and grafting reaction rate of CMCTS-g-
mPEG-CHO/HCPT from the equations displayed in Section 2.7.
Drug
loading
eﬃciency
(%)
Graft
volume
(%)
Grafting
degree of
substitution
(%)
Grafting
reaction
rate (%)
CMCTS-g-mPEG-
CHO/HCPT 2.14 75.26 43.55 96.30
instrument (Switzerland). The samples were dissolved in
DMSO. The chemical shifts were represented in ppm, based
on the signal for TMS as a reference.
2.5.3.X-RrayDiﬀraction(XRD). XRDanalysisofdispersions
in the form of thin ﬁlms was performed on randomly ori-
ented samples, scanning over the interval 5–60◦ 2θ,i n
a Rigaku D/Max2500VC/PC X-ray generator (Japan).
2.5.4. Transmission Electron Microscopy (TEM). An H-800
transmission electron microscope (Japan) was used to
characterize the size and morphology of the dried car-
boxymethylchitosan nanoparticles. For TEM observation,
the solid dispersion dissolved in distilled water and the car-
boxymethylchitosan nanoparticles were prepared from the
reaction mixture after dialysis at a proper concentration. The
sample for TEM analysis was obtained by placing a drop of
the colloid dispersion containing the chitosan nanoparticles
onto a carbon-coated copper grid. It was dried at room
temperature and then examined using TEM without any
further modiﬁcation or coating.
2.6. Solubility Study of HCPT/mPEG-CHO. An excess
amount of HCPT/mPEG-CHO was placed into a vial with
20mL water. The samples were shaken for at least 6 hours
at 25 ± 2◦C. 5mL samples were taken from the saturated
solutions and ﬁltered through a 0.22μm ﬁlter. The drug
concentration was detected UV spectrophotometrically at
λ = 384nm after appropriate dilution with demineralized
water and equated to the drug solubility.4 ISRN Pharmaceutics
Table 3: Solubility of solid dispersions.
Composition (w/w) (%) Absorbance (A) Solubility (μg/mL)
HCPT 0.093 1.19
1% 0.508 25.82
3% 0.33 16.45
5% 0.164 7.71
2.7. Drug Loading Eﬃciency, Graft Volume, Grafting Degree
of Substitution, and Grafting Reaction Rate of HCPT/mPEG-
g-CMCTS. To determine the free HCPT during prepara-
tion of the HCPT/mPEG-g-CMCTS, 20mg HCPT/mPEG-g-
CMCTS was dissolved in distilled water to a certain concen-
tration. The weight of free HCPT in the solution was deter-
mined by UV-vis spectrophotometry (UV-3210, Hitachi,
Japan) using a wavelength of 384nm. The HCPT loading
eﬃciency was calculated as follows:
(i) HCPT loading eﬃciency (%) = 100 × (the weight
of HCPT in HCPT/mPEG-g-CMCTS)/the weight of
HCPT/mPEG-g-CMCTS.
The graft volume, grafting degree of substitution and
grafting reaction rate which reﬂect the degree of the reaction
were calculated by the product weights as follows:
(i) Grafted volume (%) = 100 × (the quantity of mPEG-
CHO in HCPT/mPEG-g-CMCTS)/the quantity of
HCPT/mPEG-g-CMCTS.
(ii) Graftingreactionrate(%)=100×(themolarvolume
of mPEG-CHO in HCPT/mPEG-g-CMCTS)/the to-
tal molar volume of aldehyde.
(iii) Grafting degree of substitution (%) = 100 × (the
molar volume of mPEG-CHO in HCPT/mPEG-g-
CMCTS)/the molar volume of carboxymethylchi-
tosan unit.
These data are presented in Table 2.
2.8. Release Experiments. All release experiments were per-
formedinadialysismembranebag(MWCO=8,000–16,000)
in a shaker incubator (THZ-92A, Boxun, China) at 150rpm.
20mL of the micelles with drug solution was placed in
the dialysis bag and then immerged in the release medium
300mL at 37 ± 0.5◦C. The phosphate buﬀer solution (PBS,
pH 7.4) was used as the release medium. At the desired time
interval, any drug release in the solution was detected by UV
spectroscopy(UV-3210,Hitachi,Japan)at384nmforHCPT.
And then the fresh release medium was added to maintain
the constant volume.
Properties of pH-sensitive release experiment carried out
in pH = 4.5, 5.4, and 7.4 phosphate buﬀer solutions.
3. Results andDiscussion
3.1. Preparation of mPEG-CHO. It is easy to obtain mPEG-
CHO by oxidation of mPEG with DMSO/acetic anhydride.
Figure 1 showed the FTIR spectrum of mPEG-CHO. New
formed absorption bands of 1737cm−1 refer to the aldehyde
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Figure 3: FTIR spectra of CMCTS-g-mPEG-CHO/HCPT (a),
HCPT/mPEG-CHO (b), and CMCTS (c).
carbonyl C=O stretching vibration, indicating that mPEG-
CHO has been successfully synthesized.
3.2. Preparation of Solid Dispersion. mPEG-CHO solid dis-
persion was easy to be produced by the solvent evaporation
method. Diﬀerent weight of HCPT was dissolved in the
mPEG-CHO during preparation. Upon cooling, the drug
could either remain dissolved in the carrier (solid solution)
orprecipitateinamorphousorcrystallineform(soliddisper-
sion).
The FTIR spectrum of HCPT/mPEG-CHO was pre-
sented in Figure 2. The spectrum of HCPT/mPEG-CHO is
almost the same with mPEG-CHO, which is due to mPEG-
CHO occupying most of the proportion of the prod-
uct. The characteristic absorption bands (3626cm−1 and
1592cm−1) were consistent with HCPT, conﬁrming the
presence of HCPT. The aldehyde carbonyl C=O stretching
vibration of mPEG-CHO (1741cm−1) merged with the
lactone band (1747cm−1) of HCPT, resulting in the peak
intensity of the characteristic absorption band (1741cm−1)
in HCPT/mPEG-CHO was larger. No new bands formed
between HCPT and mPEG-CHO indicated that there is only
the physical eﬀect during the preparation process of solid
dispersion.
3.3. Synthesis of Grafted Carboxymethylchitosan Nanoparti-
cles. Schiﬀ base is a chemical bond which is acid sensitive
at pH = 5.4 consistent with the pH of tumor tissue. So
that the formed HCPT/mPEG-g-CMCTS particles might
give the antitumor drug passive targeting after combining.
Therefore, they have great potential for the further use
in the drug delivery and release ﬁelds. Here we report
our successful quest for synthesis of nanoparticles in water
without the addition of any surfactant or organic solvent
under mild conditions. The grafted Carboxymethylchitosan
nanoparticles HCPT/mPEG-g-CMCTS were prepared by
the chemical modiﬁcation of carboxymethylchitosan linear
chains using mPEG-CHO at the molar ratio (aldehyde
content/amino group content) of 1/1. The product could not
only have the advantage of solid dispersion, but also be with
the nature of acid activity.ISRN Pharmaceutics 5
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HCPT/mPEG-CHO solid dispersions (c).
According to the characteristic spectra of the HCPT/
mPEG-CHO, CMCTS, and grafted polymer in Figure 3,a n
attempt was made to determine the eventual presence of
interactions (possible interactions) between carboxymethyl-
chitosan and mPEG-CHO. The characteristic absorption
bands (1741cm−1) of HCPT/mPEG-CHO disappeared,
indicating that aldehyde has been successfully involved in
thereaction.Thecharacteristicabsorptionbands(3846cm−1
and 1383cm−1) of the grafted polymer were consistent
with CMCTS, conﬁrming the presence of CMCTS. The
characteristic absorption bands of HCPT/mPEG-g-CMCTS
were around 1627cm−1 which conﬁrmed the presence of
C=N in polymer. And it (1627cm−1)m e r g e dw i t hc a r b o x y l
stretching bands (1620cm−1) of carboxymethylchitosan.
This illustrates the success of Schiﬀ-base reaction.
The structure of grafted polymer was shown in Scheme 1
and the 1H-NMR spectrum of grafted polymer was pre-
sented in Figure 4, which made further conﬁrmation of its
molecular structure. Typical peaks at 3.38–3.71ppm (H3,
4, 5) and 3.3ppm (H8) are assigned to the ring methane
and methylene protons of carboxymethylchitosan saccharide
units and methylene groups of mPEG. The linkage between
carboxymethylchitosan and mPEG was conﬁrmed by the
appearance of a peak of –N=CHCH2O– at 2.59ppm (H7).
Peaks at 7.37–8.57ppm are attributed to benzene ring
protons from HCPT.
3.4. Physical Characterization of Solid Dispersions. XRD
diﬀraction patterns of HCPT, mPEG-CHO, and its HCPT/
mPEG-CHO solid dispersions revealed that HCPT is a crys-
talline compound, showing a very strong diﬀraction peak at
2θ of 10◦,1 3 ◦,1 9 ◦,a n d2 3 ◦.H o w e v e r ,e v e nt h o u g hi ti sa
crystalline material, its dispersions in the mPEG matrix are
completely amorphous. Only two broad peaks at 2θ of 19◦
and 23◦ that correspond to the diﬀraction pattern of pure
mPEG-CHO are recorded, while peaks that correspond to
HCPT crystals completely disappear, suggesting that the
mPEG-CHO matrix inhibits the crystallization of HCPT
(Figure 5).
3.5. Solubility Study of HCPT/mPEG-CHO. Table 3 shows
the apparent solubility of HCPT of solid dispersions in
water at 25◦C. MPEG could increase the solubility of HCPT.
Compared with the original drug, the increase in HCPT
solubility was up to 21-fold. With the increasing of the
amount of mPEG-CHO, solubility of HCPT gave out an
upward trend which was from 7.71μg/mL to 25.82μg/mL.
The increase in solubility of HCPT by mPEG-CHO may
probably be due to the formation of soluble complexes
between water-soluble polymeric carrier and poorly soluble
drug. Solubilization of solid dispersion is mainly reﬂected
in two aspects: ﬁrst is to increase the dispersion of drugs.
Drug presented colloidal, microcrystalline, and other highly
fragmented state in the carriers with very small particle size
which could improve solubility of the drug. Secondly, the
carriers can prevent crystallization of the drug. It could keep
high-energy state in the carriers so that the solubility was6 ISRN Pharmaceutics
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Figure 6: TEM images of solid dispersions after 1 day soaking in water (a), 2 days (b), 7 days (c), and 15 days (d).
600nm
Figure 7: TEM image of HCPT/mPEG-g-CMCTS nanoparticles.
improved. The results indicated that the solubility of HCPT
in water could be changed by adjusting the amount of mPEG
in solid dispersions, which can meet the diﬀerent needs in
pharmaceutical preparation.
3.6. Morphological Characterization of Solid Dispersions and
Carboxymethylchitosan Nanoparticles. Figure 6 presents the
TEM images of solid dispersions in water. They could assem-
ble to spherical nanoparticles with regular morphology in
aqueous solution. A large number of clusters appear in
the view which cannot constitute certain morphology after
one day soaking in water; after that, the clusters begin to
spread out to form sphere particles, but the aggregation
phenomenon still exist. 7 days later, particles become fuller
sphere balls with the diameter of 500nm which are not
completelyseparated.Inthefollowing8days,alltheparticles
become separate and have good dispersion in water with
the diameter of 350nm. It can be concluded that with
the extension of immersing time in water, particles could
readjust so that the surface is smoother and the balls are
plumper. In addition, the particles have little change after
storage for 5 months indicate that the solid dispersions have
high drug stability.
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The TEM image of HCPT/mPEG-g-CMCTS nanopar-
ticles was presented in Figure 7.A f t e rr e a c t e dw i t hc a r -
boxymethylchitosan, the diameter of particles went up to
800nm. But there is little change in particle morphology. All
the spherical particles are separate and have good dispersion
in water.
3.7. In Vitro Drug Release
3.7.1. Drug Release from Solid Dispersion in Three Diﬀerent
Buﬀers. In an eﬀort to study the eﬀect of release property of
soliddispersiononreleaseratesofHCPTfromnanoparticles,
we have ﬁrst taken the solid dispersions and compared their
release rates in these three buﬀers. Results were showed in
Figure8.Here,wefoundthatthereleaseratesvarydepending
upon the release media. The cumulative release percentage
are 30%, 20%, and 17% in pH 5.4, pH 4.5, and pH 7.4,
respectively. The drug release from solid dispersion wasISRN Pharmaceutics 7
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Figure 10: HCPT releasing proﬁles from nanoparticles in three
diﬀerent buﬀers.
signﬁcantly more in acid environment than that in neutral
condition which is the same as our previous work. It should
be the inherent nature of mPEG.
3.7.2. Drug Release from Carboxymethylchitosan Nanoparti-
cles in pH 7.4 Buﬀer. In vitro drug release was performed
in pH 7.4 phosphate buﬀer solution for 85h. Results of
percent drug release versus time for original drug HCPT
and HCPT/mPEG-g-CMCTS are presented in Figure 9.T h e
dissolution of pure HCPT occurred very fast, the cumulative
release percentage is up to 70% in 85h. On the other
hand, drug-loaded formulations released the drug slowly; it
released only about 15% over a period of 85h. It may be
noted that the cumulative release increased slowly after the
burst release within 10h. The reason for this phenomenon
was that Schiﬀ base is stable in a relatively neutral condition.
Drug release completely accomplished through the diﬀusion
from the drug carrier. In this paper, HCPT was ﬁrst wrapped
in mPEG-CHO and then reacted with CMCTS. So HCPT
should ﬁrst break through the mPEG layer and then the
outer CMCTS layer to get into the media. Double force of
resistance made the drug release more diﬃcult so that it
needed more time to release. 80% of drug release is basically
completed in the ﬁrst 5h due to the burst release. And higher
release rate is observed due to the dissolution of surface-
adhered drug from the carrier. At longer time, drug release
is due to the diﬀusion process, which is much slower when
compared to the initial release.
3.7.3. Drug Release from Carboxymethylchitosan Nanoparti-
cles in Three Diﬀerent Buﬀers. Figure 10 presents the releas-
ing proﬁles of HCPT from HCPT/mPEG-g-CMCTS in three
diﬀerent buﬀers. The release rate of HCPT from this conju-
gateinpH5.4wasmuchhigherthanthatintheenvironment
of pH 7.4 and pH 4.5. The cumulative release percentages
are 45%, 25%, and 15%, respectively. Release was rapid at
ﬁrst, and then slowed down, gave out a ﬂat trend at last
showing ladder-type model. Such results can be analyzed as
follows:intheﬁrst8h,therewasnoHCPTinmediumsothat
the concentration gradient is the largest in the whole release
process. The dissolution of surface-adhered drug makes the
higher release rates. The release curve is similar to straight
line; from 8h to 35h, the Schiﬀ base bond which is sensitive
to pH 5.4 environment cleaved so that the composite struc-
ture was broken. Drug in the inner particles began to release
and directly contacted with the media. Rapid release rate was
observeed again because there was still a large concentration
gradient until HCPT reached its temporary equilibrium.
The burst release may help maintain the patient therapeutic
regime, while the sustained release will maintain the plasma
concentration level.
It was noted that release in pH 7.4 was signiﬁcantly
lower than that in pH 5.4. Most of HCPT released from the
particles in the ﬁrst 10h because of the Schiﬀ base being
stable in a relatively neutral condition. However, we ﬁnd that
HCPT release proﬁle in pH 4.5 is always similar to that in
pH7.4environmentfrommicellesorhydrogelbecauseSchiﬀ
base is stable in such conditions in our previous study.
But here the release in pH 4.5 is much diﬀerent. Release
properties of solid dispersion made the release higher in pH
4.5 than in pH 7.4 as shown in Figure 8.
Generally speaking, release of the drug from carbox-
ymethylchitosannanoparticlesinvolvesthreediﬀerentmech-
anisms: (a) release from the surface of particles, (b) diﬀusion
through the swollen rubbery matrix, and (c) release due to
polymer erosion. So we could describe the drug release pro-
cesses according with kinetics equation Q = k1t0.5 + k2t +
k3t2 + k4t3 in the buﬀer solution. Q is the amount of drug
released at time t, k1 and k2 are the rate constants of drug
release by diﬀusion, k3 is the rate constant of drug release
because of diﬀusion through the swollen rubbery matrix, k4
is the rate constant of drug release due to polymer erosion.
Equations showed as follows:
pH = 7.4:
Q = 5.7578t0.5 −0.7850t +0 .0053t2 −2.0000 ×10
−5t3
R2 = 0.9883,
(1)8 ISRN Pharmaceutics
pH= 5.4:
Q = 2.9672t0.5 +0 .8312t − 0.0S183t2 +0 .0001t3
R2 = 0.9959,
(2)
pH = 4.5:
(i) 1–12h:
Q =− 3.1571t0.5 +3 .3726t −0.2171t2 +0 .0051t3
R2 = 0.9635,
(3)
(ii) 13–46h:
Q =− 2.4055t0.5 +1 .7190t −0.0351t2 +0 .0003t3
R2 = 0.9668,
(4)
(iii) 47–82h:
Q =− 106.3448t0.5 +24.7732t −0.2379t2 +0 .0010t3
R2 = 0.9935.
(5)
It can be concluded: drug release caused by diﬀusion
remained the dominant form in pH 5.4 environment, fol-
lowed by the relaxation of carrier. The rate constant of drug
release due to polymer erosion is very small compared to
the preceding factors, but should not be negligible; drug
release caused by diﬀusion categorically controlled the whole
release process in pH 7.4 condition; result in pH 4.5 is a little
complex. There are three stages clearly required to ﬁt the
model. In the ﬁrst 12h, drug release caused by diﬀusion and
therelaxationofcarrierwascomparative.13hlater,diﬀusion
began to control the release process. Gradually, it became
the dominant force. And this trend is more obvious after
47h. Such phenomenon occurs because the release media
inﬁltrating into the carrier have reached its limit, that is, the
relaxation of carrier has reached its saturation and does not
change any more. Diﬀusion gradually became the dominant
force. Similarly, polymer erosion cannot be ignored.
4. Conclusions
We have shown that a nanosized particle assembled from
carboxymethylchitosan using a Schiﬀ base reaction with
HCPT/mPEG-CHO solid dispersion. The advantage of this
drug model lies in two aspects: ﬁrstly, solid dispersion can
improve the solubility of HCPT greatly in water. In this
way, indissoluble drugs could have good dispersion and
high wettability in water which can accelerate the rate of
drug absorption and improve drug bioavailability; secondly,
after reacting with CMCTS, HCPT was more stable in vivo,
showing a signiﬁcantly slow release property. In addition,
the drug model in our research gave HCPT pH sensitivity
which can be attractive candidates as delivery biosystems in
tumor therapy.
Compared with the original drug, the increase in HCPT
solubility of solid dispersion was up to 21-fold. With the
increasingoftheamountofmPEG-CHO,solubilityofHCPT
gave out an upward trend which was from 7.71μg/mL to
25.82μg/mL. Colloid systems based on solid dispersion were
stable in aqueous medium at room temperature. Particle
size of HCPT/mPEG-CHO measured by TEM was around
350nm which can be achieved for passive targeting of tumor
tissue concentration. The drug release processes accorded
with kinetics equation Q = k1t0.5 + k2t + k3t2 + k4t3 in the
buﬀersolution.ThereleaserateofHCPTfromthisconjugate
in pH 5.4 was much higher than that in the environment of
pH 7.4 and pH 4.5. The cumulative release percentages are
45%, 25%, and 15%, respectively. It meant that the prepared
structure of conjugate might be unstable in the acidic
environment and the drug would be released sensitively. The
cumulativereleasepercentageofHCPTinconjugatewasonly
15% within 85h, while the original drug was up to 70%
in pH 7.4 environment, showing a signiﬁcant slow release
property.
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